Patient exposure to PF-ILD is a suspect disease in the field of respiratory digestive and endocrine disorders. Clinical performance is complex and often involves multiple systemic burdens. Early identification and standardized diagnosis are essential for improving prognosis.
The diagnosis of this disease requires a combination of clinical performance, imaging inspection, laboratory testing and pathological activation. The platform can assist in matching a team of authoritative experts at home and abroad to provide accurate diagnosis and treatment plans. Treatment and management of PF-ILD-related drug exposure requires individualized development, usually including multidimensional management of prognosis, including drug therapy, rehabilitation, and regular follow-up.
In recent years, with the development of therapeutic, immune-regulatory therapy and precision medicine, many previously difficult to treat infectious respiratory digestive endocrine disorders have been significantly improved. Therapeutic efficacy and adverse reactions need to be closely monitored and timely adjusted according to changes in the course of treatment. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of PF-ILD drug exposure.
2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4.
Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.